Kanāda - angļu - Health Canada

merck canada inc - interferon alfa-2b - liquid - 25000000unit - interferon alfa-2b 25000000unit - interferons

Kanāda - angļu - Health Canada

merck canada inc - interferon alfa-2b - liquid - 50000000unit - interferon alfa-2b 50000000unit - interferons

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 44 microgram/ml - injection, solution - excipient ingredients: mannitol; poloxamer; methionine; sodium hydroxide; acetic acid; water for injections; benzyl alcohol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 44 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; poloxamer; benzyl alcohol; methionine; acetic acid; water for injections; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 44 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; poloxamer; benzyl alcohol; methionine; acetic acid; water for injections; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - recombinant omega interferon of feline origin - immunotherapy - cat | dog - adult | cat - queen | cat - tom | kitten - canine parvovirus | feline calicivirus | calicivirus (feline) | fcv | parvovirus

Filipīnas - angļu - FDA (Food And Drug Administration)

zuellig pharma corp - peginterferon alfa-2a (40 kd) - solution for subcutaneous injection - 135mcg/0.5ml

Filipīnas - angļu - FDA (Food And Drug Administration)

zuellig pharma corp - peginterferon alfa-2a (40 kd) - solution for subcutaneous injection - 180mcg/0.5ml

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

aim immunotech inc - interferon alfa-n3 (unii: 47bpr3v3mp) (interferon alfa-n3 - unii:47bpr3v3mp) - interferon alfa-n3 5000000 [arb'u] in 1 ml

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - interferon alfa-2b - eye drops - 1mega unit/1ml